Trial
NCT05135650
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Marrow Donor Program; Vir Biotechnology, Inc.
Condition
COVID-19 Infection
Intervention
Questionnaire Administration
Why stopped
Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-13